United States · Markets & Finance · CNBC

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Published by CNBC · United States 41 min ago

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.

Read the full article on CNBC Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.cnbc.com)

Also worth reading

Energy's inverse grip on stock market hits a record high

Nvidia hits record close, nears unprecedented $6 trillion valuation

Mash-Up of Paramount and Warner Bros. Will Be Called Skydance

Business Insider

Data centers and healthcare were bright spots in the rough September jobs report

It’s not AI anymore, it’s ‘super intelligence’ (according to the White House)

Once a $2.3 Billion Network, Ethereum Layer-2 Blast Is Shutting Down